The Fellow on Call | Blood Cancers Today (2024)

The Fellow on Call: The Heme/Onc Podcast is dedicated to bringing its listeners the fundamentals, core concepts, and important management approaches in the field of hematology and oncology, driven by the latest evidence and expert opinion. In each episode, the hosts provide answers to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to nurses, advanced practice providers, and practicing physicians.

In this episode of "The Fellow on Call," the hosts discuss approaches to primary refractory diffuse large B-cell lymphoma.

In this episode of "The Fellow on Call," the hosts discuss relapsed DLBCL, CAR-T versus autologous transplant, and more.

In this episode of "The Fellow on Call," the hosts focus on primary refractory DLBCL, CAR-T therapy, and more.

In this episode of "The Fellow on Call," the hosts focus on CAR-T, bispecific antibodies, and more.

In the third episode of the DLBCL series, the hosts discuss how to manage DLBCL in the advanced stages of the disease.

In this episode of "The Fellow on Call," the DLBCL series continues with a focus on treatment and management strategies.

In this episode of "The Fellow on Call," the hosts kick off a new series focusing on DLBCL.

The hosts discuss how classical Hodgkin's lymphoma is currently treated and the implications of data from SWOG 1826.

Dr. Manni Mohyuddin discusses multiple myeloma treatment as an art where clinicians take imperfect data to treat patients.

The ins and outs of molecular testing with The Fellow on Call.

In this podcast episode of The Fellow on Call, they discuss the application of flow cytometry in hematologic malignancies.

Why do we use lenalidomide maintenance therapy post-stem cell transplant?

The Fellow On Call break down immunochemistry in hematologic pathology.

Part two of the Heme Path Series is a debate on two cytogenetic methodologies: FISH and conventional karotype.

The Fellow on Call discuss MGUS and smoldering myeloma.

The Fellow on Call recount key trials in autologous transplant in multiple myeloma.

A discussion on transplant in myeloma and real-life decision-making.

In part six of the Myeloma Series, a historical perspective on the treatment evolution of myeloma.

The Fellow on Call discuss APL, a true hematologic emergency.

The Fellow on Call discuss plasma cell dyscrasias and MGUS.

The third part of the Myeloma Series discusses risk stratification and treatment response monitoring in these patients.

A discussion on myeloma pharmacology with Kathryn Maples, Pharm D, BCOP.

Ronak Mistry, DO

Vivek Patel, MD

Dan Hausrath, MD